Group 1 - The company, Changfeng Pharmaceutical, plans to conduct an initial public offering (IPO) from September 26 to October 2, 2025, offering 41.198 million H-shares at a price of HKD 14.75 per share, with 10% allocated for Hong Kong and 90% for international sales [1] - The company specializes in the research, development, production, and commercialization of inhalation technology and inhalation drugs, focusing on respiratory diseases, and has received six product approvals from the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) [1] - The company's revenue for the years 2022, 2023, 2024, and the three months ending March 31, 2025, were RMB 349 million, RMB 556 million, RMB 608 million, RMB 140 million, and RMB 136 million, respectively, with gross profits of RMB 268 million, RMB 458 million, RMB 491 million, RMB 115 million, and RMB 108 million [1] Group 2 - Assuming the offering price of HKD 14.75 per share, the company estimates a net proceeds of approximately HKD 525 million from the global offering [2] - The estimated net proceeds will be allocated as follows: approximately 40% for ongoing research and development of inhalation formulation candidates, 20% for preclinical research funding for various pipeline programs and technologies, 30% for expansion and upgrading of production facilities and equipment, and 10% for working capital and other general corporate purposes [2]
长风药业9月26日-10月2日招股 拟全球发售4119.8万股H股
Zhi Tong Cai Jing·2025-09-26 00:12